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Reflective Essay
I’m setting out to eradicate measles from our planet. I want to save the lives of
children in Africa where wars prevent them from being vaccinated. I want to save
refugee children in Haiti, Myanmar, Syria, Somalia, and so many other countries who
are not vaccinated because they have left their countries and are migrants. I want to
save the lives of American children, the underimmunized Orthodox Jewish people of
New York City, Amish of Ohio, and citizens of Vashon Island, Washington--all locations
where measles outbreaks have occurred in the United States. My vision is conceivable
because of the foundational work that has come before me and its comprehensive
characterization in scientific literature and the history of science.
Our library matters. For instance, my engagement with Claremont Colleges
library services enabled me to read the primary journal articles detailing the successful
campaign to globally eradicate smallpox. I had access to critical supportive manuscripts
from the 80’s characterizing the safety of aerosolized measles vaccination in almost four
million children in Mexico. Claremont Colleges library services provided me the original
vision of Albert Sabin who, after helping eradicate polio, set his sights on measles and
conducted aerosolized measles vaccination campaigns before his death in 1993.
For the citation format and source selection for this paper, I am grateful for Adam
Rosenkranz who shared his valuable time with my integrated biology and chemistry
(IBC) class during my freshman year to teach us how to correctly format our citations,
ensure that we are citing reliable and appropriate sources, and have the tools
necessary to maneuver the omnipotent advanced search option on the library website.
Using what Adam Rosenkranz taught me, all sources that I have cited in my research
have been peer-reviewed including the national/global databases from the WHO and
the CDC.
Before the COVID-19 pandemic, the basement of the library is where I spent my
weekends and weeknights, curled up on the green couches at the bottom of the stacks
with my roommates reading interesting books we found on the shelves, like Paul
Ewald’s Evolution of infectious diseases found on the first floor of the library. The library
enabled me to grow myself as a scholar studying infectious diseases as well as a
person. My first date, freshman year, was a study date in the basement of the library by
the old map section where we worked on a psychology problem set until the
announcement that the library was closing echoed through the halls. On the second
floor, in the private rooms to the left of the stacks, my friend from Harvey Mudd and I
sketched out the first design of a noninvasive inexpensive diagnostic device for
detection of malaria that set me on a track to study infectious diseases. On the top floor
of the library, on the blue and black couches by the elevator, I used the focused quiet
space to study day and night for my organic chemistry final which reinforced my love of
and commitment to science. In the Fall of 2021, I intend to convene an advisory panel I

have named MEST, Measles Eradication Super Team, in which our first meeting will
take place in the library--where it all started for me.
As the COVID-19 pandemic hit, overnight, we unpinned our Thelonious Monk
posters off the wall, packed our belongings into cardboard boxes and headed to
scattered homes, awkwardly disrupting our sophomore college year. Remarkably
though, the pandemic afforded me stunning opportunities. On my train ride home from
Pitzer College, I read a book about viruses and zoonotic infections titled Spillover:
Animal Infections and the Next Human Pandemic by David Quammen and was at once
transfixed. After that moment, I tried to learn everything I could about viruses and found
myself in the laboratory of virologist Dr. Gene Tan of the J. Craig Venter Institute (JCVI).
I believe we underestimate measles. Over 100,000 children continue to die each
year from preventable measles. Measles vaccination rates have declined because of
the pandemic. Measles is a persistent problem and globally we now have a real
opportunity to eradicate it once and for all. Through my personal experience
volunteering in a SARS-CoV-2 vaccination supersite as a nationally certified emergency
medical technician (EMT), I personally observed the challenges of moving the fragile
vaccines from freezers to syringes, and finally to arms. The difficulty rapidly responding
to viral outbreaks in developing nations now felt exceptionally real. Moreover, vaccine
hesitation was an impactful social movement that we’d need to face with compassion
and evidence.
I have come to my measles vaccine interests quite naturally (Figure 1). In 2014
my grandfather, Dr. Robert Sievers, assembled a measles task-force and received a
$20 million grant from the Gates Foundation to develop a dry inhalable measles vaccine
and pushed it through a phase I clinical trial. In 2020, my father, Dr. Eric Sievers, is
developing a bacteria-vectored SARS-CoV-2 vaccine and is currently in phase I clinical
trials. In 2021, I intend to pick up where my grandfather left off and proceed onwards
with a phase II clinical trial of the measles inhalable vaccine and work towards the
implementation of flash-bang vaccination and ultimately the global eradication of
measles.
We have a remarkable opportunity to make a difference with measles right now.
With the culmination of technological advancements in surveillance and rapid
vaccination that have been primed and perfect over hundreds of years paired with a
world hungry to stomp out SARS-CoV-2, measles eradication is an achievable goal. I
look forward to the time when I get to sit and read by the towering windows behind the
stacks about measles and draft an eradication plan. Measles has overstayed its
welcome, it’s time to end it once and for all.
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Figure 1. My 11-year-old self, Benjamin Sievers, demonstrating inhalation of a mock dry
powder measles vaccine delivered by my grandfather, Robert Sievers. Image taken
from the article “The Man Fighting Measles One Breath at a Time” published by the
University of Colorado Boulder Alumni Magazine in 2011.

Measles Eradication: Let’s Root Out Measles, Ring-vaccinate Hotspots, and
Eradicate this Deadly Scourge Forever
Abstract
Amidst an unremitting pandemic, we have become amatuer virologists. Let's now
summon our collective spirit and wipe measles from our planet. Why measles? Well, it
is a dreadful and deeply impactful infection. First, it kills over 200,000 children every
year. Those who survive infection often subsequently experience profound “immune
amnesia” that puts them at increased risk from other infections. All of this can be
prevented through safe and effective measles vaccination. It is unconscionable that
more children worldwide are now dying from measles than in nearly a quarter century.
Second, thanks to our current pandemic, shared interest in virology and vaccine
awareness is robust. Many of us now view vaccines as our collective salvation for both
individual health and our global economy. What an exceptional opportunity! So let’s
vaccinate for measles while we all care about viruses. Third, global cooperation is
improved, we are better able to rapidly detect measles outbreaks, and inhaled measles
vaccines have been shown to be safe. A global eradication campaign based upon these
elements has the potential to eradicate measles once and for all. Finally, a persistent,
humanitarian call to action over decades has helped surface the pitfalls and illuminate
the road to success, as demonstrated through the thoughtful and strategic eradication of
smallpox that culminated in 1979. During those heady, optimistic years the US Center
for Disease Control set a four-year goal to eradicate measles in the United States by
1982. We collectively came close: the measles incidence in the United States fell to
nearly zero. Since that time, the global incidence of measles has rebounded vigorously.
Worldwide, there were more cases of measles in the first six months of 2019 alone than
in any full year since 2006. We now need to arrest our backward slide by using novel,
highly sensitive technology to track regional outbreaks and innovative inhaled vaccine
delivery approaches to more easily and rapidly increase herd immunity. Let’s step up,
act decisively, and eradicate measles forever to save millions of lives over the coming
decades.

2.1 A Global Education Regarding Viruses and the Power of Vaccination
Rarely in history has there existed a shared conversation that spans all religions,
languages, and borders. The dialogue regarding the SARS-CoV-2 virus has generally
inspired deeper respect for vaccines. The momentum is tangible and we are on track for
global mass vaccination to prevent death and severe morbidity from COVID-19. In
2020, nearly 4% of the world’s research output was dedicated to SARS-CoV-2 with over
200,000 publications about COVID-19 and more than 30,000 COVID-19 preprints, many

of them related to vaccinology and combating the virus [1]. Compared with
pre-pandemic levels of interest, a large proportion of global populations has indicated a
willingness to vaccinate.
Sometimes we forget that measles is a ferocious virus. Although the majority of
infected individuals have fever and moderate misery they often recover without chronic
complications. However, predominantly in developing countries, devastating
complications arise leading to serious illness, hospitalization, and in some cases death.
For every 10,000 measles infected individuals, 2,500 people will be hospitalized and
1,000-2,000 people will die [2]. In almost all cases infected individuals suffer abject
misery for approximately two weeks.
In tandem with its disease burden, measles is as contagious as it is harmful.
Measles is so contagious that for much of human history, infection was practically
universal in childhood. Before an available vaccine, the Centers for Disease Control and
Prevention (CDC) estimated that children in the United States experienced several
million cases yearly, resulting in approximately 500 deaths, 1,000 cases of encephalitis,
and 48,000 hospitalizations every year [3]. In epidemiology, the basic reproductive
number is the expected number of infections generated by a single case, meaning how
many people can a single infected person spread the virus to. Each person infected with
measles typically transmits it to another 12 to 18 other people--six times more infectious
than SARS-CoV-2 [4, 5].
Vaccination was an unequivocal success. The first measles vaccine, a
live-attenuated vaccine known as the Edmonston-B strain, was developed and licensed
by John Enders and his colleagues in 1963 [6]. Through intense empirical development,
the vaccine was created through attenuation of wild-type measles [7]. The 1963
measles vaccine is the same vaccine we use for measles today. After the creation of
the safe vaccine a wave of relief swept over the United States and people buzzed with
excitement as a public health victory potentially stood before us, the CDC publishing a
document titled Measles Eradication 1967, and a measles eradication movement
backed by President Lyndon Johnson formed [8, 9].
In 1998, broad celebration regarding the public health value of measles
vaccination was placed at risk following the publication of what was later determined to
be a falsified study that claimed a causal relationship between receipt of the MMR
vaccine (measles, mumps, and rubella) and the development of autism. As a
preponderance of studies have since demonstrated, the measles vaccine has been
confirmed to be a safe vaccine [10]. Ultimately, the Wakefield manuscript was retracted
in 2010 [11]. Multiple followup studies were conducted with large, statistically compelling
sample sizes and proved no connection between the MMR vaccine and autism [12].
Despite its terrifyingly high reproductive number and consequential pathogenicity,
measles has one defining feature that can be used against the virus - measles has no
nonhuman reservoirs. Unlike many viruses that plague humans, measles is not a

zoonotic virus and thus can only propagate in human hosts making eradication of
measles feasible through continued widespread use of intramuscular measles vaccines
and methodical tracking of new measles outbreaks coupled with immediate ring
vaccination responses when they occur. Once measles is eliminated in humans it will be
eliminated forever. It will take an inspired, enduring, coordinated, global push to
completely eradicate measles from the planet--one akin to the collective efforts
deployed to eradicate smallpox. We can do this. We’ve done it before.
The global eradication campaigns, including the 1967 measles eradication
campaign in the United States and the 1985 national immunization program in India,
profoundly reduced the incidence of measles worldwide, but unfortunately did not lead
to absolute eradication (Figure 1). In 2018 alone, measles cases surged to
approximately 10 million cases worldwide with 140,000 deaths, a 58% increase since
2016 [13]. With a safe, inexpensive, highly protective injectable vaccine widely
available, why haven’t we eliminated measles globally? And how can measles incidence
be again on the rise? Wealthy nations, including the United States, have recently
experienced scattered measles outbreaks as a result of vaccine hesitancy. In contrast,
in developing nations, measles outbreaks have persisted because of a lack of access to
vaccination to the people who need it most due to wars, political conflicts, unavailability
of healthcare, inadequate medical infrastructure, and ultimately, a failure of will.

Figure 1. Reported measles cases in the United States by year from 1980 to 2018.
Measles cases are defined as epidemiologically linked, clinical and laboratory confirmed
cases as reported by the World Health Organization (WHO). Data to create this graph
was retrieved from the WHO global measles summary in February 2021.

2.2 Measles can be Deadly; Measles Vaccination is Safe and Effective
Measles is particularly deadly for those living in developing countries. According
to the World Health Organization, the death rate of measles in developing nations
hovers around 2-15% and has the potential to jump up to 25% in the worst outbreaks,
particularly when local health systems are overwhelmed [14]. Measles survivors
experience considerable morbidity and can be left with permanent disabilities, including
deafness, blindness, and even brain damage [15]. Primarily found in children, measles
has the ability to induce a phenomenon known as immune amnesia, where the measles
virus erases 11-73% of the patient’s capability to produce antibodies against
previously-encountered pathogens as the virus targets plasma cells in the bone marrow
[16]. This can cause children who are recovering from measles to suffer from another
pathogen that they were previously protected from prior to their measles infection.
Two doses of the MMR vaccine is 88% (95% CI: 62-96%) effective in preventing
measles [17]. In many poor countries, children are fortunate to even receive a single
dose of the vaccine. In the Democratic Republic of the Congo (DRC), in 2018, 57% of
children received a single dose of the measles vaccine according to a UNICEF study
[18]. In order to prevent outbreaks of measles in a population, it is estimated that
92-95% of the population needs to be fully immunized with two doses to achieve herd
immunity [19]. Making matters more challenging, the MMR vaccine must be kept
between 2℃ and 8℃ from the moment vials are pulled from refrigerated storage until
the vaccine is injected into the upper arm. Healthcare workers need the necessary
training to safely inject the vaccine, a problem we did not face with the oral poliovirus
vaccine [20].
Remarkably, even though vaccination costs US$1.80 per child, eradication
campaigns can be prohibitively costly. Moreover, African countries with few additional
resources have been required to fund a portion of campaigns [21]. In 2010, the DRC
was unable to cover the costs of the vaccination campaign, resulting in an unremitting
measles outbreak that lasted 30 months [22]. Taken together, measles eradication
campaigns have met limited success for manifold reasons including lack of funding,
political instability, a challenged infrastructure for storage and administration of the
vaccine, and ultimately, a paucity of trained vaccinators. Although these deficiencies
might argue to supplant the standard intramuscular injection of measles vaccine, a
counter argument can be made to bolster the standard approach with rapid response to
outbreaks with novel inhaled vaccinations. Simply put, we should continue to embrace
effective established technology when and where these approaches optimally serve and
look to new strategies where conventional vaccination campaigns fall short. For
example, cold-chain dependent intramuscular measles vaccines might be well-suited
and familiar for urban settings while dry-powder, inhaled measles vaccine might

represent a better fit for rural settings lacking trained vaccinators, refrigeration, and
established medical infrastructure. Ultimately, blending established approaches with
newer technologies has the best potential to accomplish protective herd immunity levels
that can achieve global eradication.
2.2.1 Liquid Aerosolized Measles Vaccine
Recognizing the limitations of intramuscular injection of the measles vaccine, the
concept of the aerosolized measles vaccine was originally envisioned by Albert Sabin,
and aimed to be a vaccine that was needle-free, simple, safe, inexpensive, and easily
deployed in mass vaccination campaigns [23]. A jet nebulizer was used to generate
liquid aerosolized vaccine particles for inhalation. Through substantial clinical testing,
the liquid aerosolized measles vaccine was shown to be both safe and well-tolerated,
producing similar immune responses as the subcutaneous vaccination. Nearly 4 million
children were vaccinated against measles in a mass aerosolized measles vaccination
program conducted in Mexico between 1982 and 1990. Both primary and booster doses
of the inhaled aerosolized Edmonston-Zagreb measles vaccine were delivered by
nebulization using an electric air compressor and disposable paper cones.
The aerosolized vaccine program was a remarkable success, leading to
containment of the 1980s measles epidemic in Mexico [24]. In a followup confirmatory
study, children vaccinated against measles by the aerosol route demonstrated a
vaccine effectiveness of 92% that was comparable to the effectiveness of the
subcutaneous measles vaccination via intramuscular injection [25]. Over a decade later,
in a clinical trial conducted in 2004, 59 children ages 11-13 months, were vaccinated
with the aerosolized measles vaccine, in which 77.5% of the children had presence of
measles antibodies >120 mIU/ml as read through plaque reduction assays. Among the
children in this study, 91% of them vaccinated through the aerosolized measles vaccine
had detectable measles PRN antibodies and an SI of ≥3.0 [26]. A systematic review of
the liquid aerosolized measles vaccine concluded that aerosolized liquid mist vaccine
was immunogenic, safe, and well-tolerated [27]. Notably, the aerosolized measles,
mumps, and rubella combination vaccine has also been shown to induce immune
responses that are similar or in some cases superior to the subcutaneous vaccine [28].
2.2.2 Inhaled Dry Powder, Temperature Stable Measles Vaccine
Although wet mist aerosolized measles vaccination campaigns are feasible, there
are considerable additional benefits that can be achieved using dry powder inhalation
formulations. Conceivably, some dry powder formulations can be stored at room
temperature for prolonged periods and inexpensive single-use inhaled dose devices
may be much easier to deploy urgently in outbreak settings. The Bill and Melinda Gates

Foundation supported evaluation of a needle-free, temperature stable dry powder
measles vaccine as a part of the Grand Challenges in Global Health initiative in the
early 2000s. Exploratory manufacturing and preclinical work ultimately led to a
successful phase I clinical study that confirmed safety of an inhalable dry powder
measles vaccine in 60 measles-antibody-seropositive adult males of 18-45 years of
age. Measles antibody titers were measured 7 days before vaccination and at 21 and
77 days post vaccination by ELISA and plaque reduction neutralization assays. All
individuals were seropositive for measles and had a baseline titer of <120 mIU as
measured by plaque reduction neutralization test (PRN) on day 7. The dry powder
measles vaccine was well tolerated in all subjects and had an immunogenicity profile
comparable to the widely used subcutaneous measles vaccine.
Utilizing the plaque reduction neutralization test, the gold standard for assessing
measles immunity as PRN titers are directly correlated with measles immunity, a person
with a PRN titer of under 120 mIU/ml is of high risk for measles disease if exposed to
the virus [29]. On the other hand, persons with PRN titers of 120-1052 mIU/ml are often
protected from measles disease but have the potential to acquire subclinical measles
infection if exposed to the virus. For persons with PRN titers of greater than 1052
mIU/ml, they are highly unlikely to become infected by measles and/or develop an
immune response post vaccination [30]. Approximately half of the cohort of patients with
baseline PRN titers of 120-1052 mIU/ml experienced a four-fold increase in titer 28 or
84 days post vaccination [31]. For all of the patients, the dry powder inhaled vaccine
increased the measles antibody titers whilst simultaneously maintaining a reassuring
safety profile. The dry powder vaccination cost per dose in the developing world was
anticipated to be US$0.17--a tiny fraction of the cost for intramuscular injections.
2.3 Diagnostic Technology
Timing matters in accurate measles diagnostics. From a measles eradication
perspective, once infections are identified through reports of the classic skin rash, an
outbreak is most certainly in full bloom. Rapid detection of a measles infection is
critically important as it enables the initiation of rapid booster vaccination of exposed
persons. For exposed, non-immunized people like pre-vaccinated infants, a measles
vaccination can be given within 72 hours and can prevent or greatly reduce the severity
and time of the illness. And this is where an easily stored, dry powder inhaled vaccine
might have the greatest impact. Imagine thousands of self-inhalation doses stored at
geographical locations that can be swiftly deployed to outbreaks for rapid ring
vaccination. As rapid assembly of trained vaccinators to inject conventional vaccines
simply isn’t feasible, self-administration of inhaled vaccines provides a key to success.
Measles infections are identified by the appearance of erythematous
maculopapular (non-vesicular) rashes developing cephalocaudally and at least one of

the three “C”s: cough, coryza, or conjunctivitis. However it is readily evident that routine
surveillance with reverse transcriptase-polymerase chain reaction (RT-PCR) tests that
can detect viral RNA from blood, nasal, throat, or urine samples has the potential to
identify outbreaks before they infect large communities [32]. There are multiple
surveillance systems set forth to track, control, and monitor on both the national and
global scale like the National Notifiable Diseases Surveillance System (NNDSS) for the
United States and the WHO’s Measles Mortality and Regional Elimination Strategic Plan
for global surveillance.
Although in 2000, the United States declared elimination (absence of continuous
disease transmission for greater than 12 months) of measles, measles cases worldwide
are once again rising. Current measles outbreaks in the United States have become a
thorny political issue. Since 2014, 75% of measles infections in the United States have
happened within closed religious communities, such as the Orthodox Jewish population
in Williamsburg, Brooklyn, the Amish populations in the Midwest, and Somali migrants
in Minnesota [33]. Current MMR vaccination rates for children of ages 19-35 months in
the United States is approximately 91% but can be as low as 60% in certain close knit
communities such as the Orthodox Jewish community in New York [34]. With low
vaccination rates and vaccine hesitancy, these communities are at enormous risk for a
larger epidemic of measles. In fact, in 2019, the World Health Organization (WHO)
named vaccine hesitancy as one of its top ten threats to global health that year [35].
2.4 The Time for the Eradication of Measles is Now
Now is a pivotal time for vaccinology and viral surveillance. New vaccine delivery
systems are available with new platforms including mRNA vaccines and an inhaled dry
powder, live-attenuated measles vaccine evaluated in humans. In addition to new
delivery systems, vaccine willingness is also at an all-time high as nations globally are
committed to vaccinate their populations to protect against SARS-CoV-2. For all these
reasons, an inexpensive, easily deployed, inhalable vaccine for measles is highly
attractive.
The demonstrated evidence showing safety and protective efficacy of
aerosolized measles vaccination in almost 4 million recipients coupled with
technological advances in dry powder delivery strategies now enable us to envision a
more effective, rapid response approach to outbreaks. Imagine the World Health
Organization receiving urgent word of a new measles outbreak among Rohingya
refugees at a large camp in Cox’s Bazar in Bangladesh. Instead of assembling 132
trained vaccinators, 264 volunteers, 1400 Community Health Workers, and 2000
Majhies as was impressively performed recently as a part of a conventional vaccination
campaign, a much smaller group of health workers would distribute single use,
biodegradable, vaccine-filled straws; a quick inhale would vaccinate and protect. There

would be no needles, no syringes, no trained vaccinators, and no dangerous sharps
requiring specialized disposal. The technology for this approach is readily available. We
now require the collective will to embrace a methodical global measles eradication
vision [36].
I envision in the next 5 years a phase II safety trial of a simplified dry powder
inhaled vaccine, through a streamlined inexpensive whistle/straw shaped device that
enables quick and effective measles vaccination. Antibody levels of dry powder inhaled
vaccine will be observed and compared with the current subcutaneous MMR vaccine.
The device will be easy-to-use, have no additional parts, and safe to receive multiple
times. Rapid deployment of these vaccines can be achieved through airdrop using
drones, the possibilities are endless. There is no better time than right now to deploy an
inhaled vaccine for measles and eradicate measles for good.
2.5 Mandate
When a disease ceases to be circulating in a region, it is considered eliminated
for that region. On the global scale, when a disease stops circulating globally it is
considered to be eradicated. Smallpox, a disease that killed approximately 35% of its
hosts and left many blind or scarred, was eradicated in 1977 [37]. Like measles,
smallpox has no non-human hosts meaning its eradication can be guaranteed once it
stops circulation in humans. A Somalian cook named Ali Maow Maalin was the last
person to be infected by wild smallpox, and on October 12th 1977 smallpox was
declared eradicated [38].
The successful eradication of smallpox was accomplished through a confluence
of continuous surveillance and a key technique known as ring vaccination. The ring
vaccination technique is used to quickly identify and isolate exposed individuals and
vaccinate them as quickly as possible, stopping the spread of the virus into the
community. Unlike smallpox with the fast detectible onset of a highly-visible rash, the
rash that forms with measles occurs later in infection with patients becoming contagious
before the appearance of the rash, making the ring vaccination technique more difficult
but nonetheless likely to succeed with a combination of rapid initiation of
easy-to-conduct, self-vaccination using a dry inhalable measles vaccine and dedicated,
enduring measles surveillance. As mentioned earlier, rapid deployment of vaccination to
exposed individuals to measles within 72 hours can change the entire course of
infection, even having the potential to stop the infection. Utilizing a new technique, I
have named “flash-bang vaccination,” I envision rapidly deployable inhalable measles
vaccine kits to quickly flood outbreak hotspots extinguishing the outbreak through mass
rapid vaccination, of both recently infected and uninfected people, vaccinated and
unvaccinated people, before it can infect any more of the community as well as
minimizing the severity of the already infected measles patients.

In two years alone, we can eradicate measles by working hand-in-hand with local
clinics, hospitals, health centers, and community centers globally, saturating outbreak
hotspots with flash-bang vaccination using dry inhalable measles vaccines before
measles can spread any further, upping our measles surveillance and outbreak
response time, and increasing vaccine awareness and the importance of vaccination.
We’ve done it before with smallpox virus and rinderpest virus, measles you’re next!
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